Intra-lesional low-dose interferon α2a therapy for primary cutaneous marginal zone B-cell lymphoma

References

• Willemze R, Jaffe E S, Burg G, Cerroni L, Berti E, Swerdlow S H, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768–3785
   PubMed Web of Science ®Google Scholar
• Hoefnagel J J, Vermeer M H, Jansen P M, Fleuren G J, Meijer C J, Willemze R. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. British Journal of Dermatology 2003; 149: 1183–1191
   PubMed Web of Science ®Google Scholar
• Dummer R, Kempf W, Hess Schmid M, Haffner A, Burg G. Therapy of cutaneous lymphoma—current practice and future developments. Onkologie 2003; 26: 366–372
   PubMed Web of Science ®Google Scholar
• Heinzerling L, Dummer R, Kempf W, Schmid M H, Burg G. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Archives of Dermatology 2000; 136: 374–378
   PubMed Web of Science ®Google Scholar
• Rubegni P, De Aloe G, Pianigiani E, Lazzi S, Fimiani M. Primary cutaneous B-cell lymphoma: treatment with low dose intralesional recombinant interferon-alpha 2A. Journal of the European Academy of Dermatology & Venereology 1999; 12: 70–71
   PubMed Web of Science ®Google Scholar
• Wollina U. Complete response of a primary cutaneous T-cell-rich B cell lymphoma treated with interferon alpha2a. Journal of Cancer Research & Clinical Oncology 1998; 124: 127–129
   PubMed Web of Science ®Google Scholar
• Kutting B, Bonsmann G, Metze D, Luger T A, Cerroni L. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. Journal of the American Academy of Dermatology 1997; 36: 311–314
   PubMed Web of Science ®Google Scholar
• Zenone T, Catimel G, Barbet N, Clavel M. Complete remission of a primary cutaneous B cell lymphoma treated with intralesional recombinant interferon alpha-2a. European Journal of Cancer 1994; 30A: 246–247
   PubMed Web of Science ®Google Scholar
• Wollina U, Hahnfeld S, Kosmehl H. Primary cutaneous marginal center lymphoma—complete remission induced by interferon alpha2a. Journal of Cancer Research & Clinical Oncology 1999; 125: 305–308
   PubMed Web of Science ®Google Scholar
• Zenahlik P, Fink-Puches R, Kapp K S, Kerl H, Cerroni L. [Therapy of primary cutaneous B-cell lymphomas]. Hautarzt 2000; 51: 19–24
   PubMed Web of Science ®Google Scholar
• Brierley M M, Fish E N. Review: IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry. Journal of Interferon & Cytokine Research 2002; 22: 835–845
   PubMed Web of Science ®Google Scholar
• Platanias L C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Natural Reviews in Immunology 2005; 5: 375–386
   PubMed Web of Science ®Google Scholar
• von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. Journal of the National Cancer Institute 2003; 95: 437–448
   PubMed Web of Science ®Google Scholar
• Brassard D L, Grace M J, Bordens R W. Interferon-alpha as an immunotherapeutic protein. Journal of Leukocyte Biology 2002; 71: 565–581
   PubMed Web of Science ®Google Scholar
• Krown S E, Real F X, Cunningham-Rundles S, Myskowski P L, Koziner B, Fein S, et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. New England Journal of Medicine 1983; 308: 1071–1076
   PubMed Web of Science ®Google Scholar
• Bunn P A, Jr, Ihde D C, Foon K A. Recombinant interferon alfa-2a, an active agent in advanced cutaneous T-cell lymphomas. International Journal of Cancer Supplement 1987; 1: 9–13
   PubMedGoogle Scholar
• Agarwala S S, Kirkwood J M. Adjuvant interferon treatment for melanoma. Hematology & Oncology Clinics of North America 1998; 12: 823–833
   PubMed Web of Science ®Google Scholar
• Edwards L, Berman B, Rapini R P, Whiting D A, Tyring S, Greenway H T, Jr, et al. Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy. Archives of Dermatology 1992; 128: 1486–1489
   PubMed Web of Science ®Google Scholar
• Tsimberidou A M, Giles F, Romaguera J, Duvic M, Kurzrock R. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer 2004; 100: 574–580
   PubMed Web of Science ®Google Scholar
• Bonkovsky H L, Clifford B D, Smith L J, Allan C, Banner B. High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial. Digestive Disease Science 1996; 41: 149–154
   PubMed Web of Science ®Google Scholar
• Iino S. High dose interferon treatment in chronic hepatitis C. Gut 1993; 34(2 Suppl)S114–S118
   PubMed Web of Science ®Google Scholar
• Davis G L, Balart L A, Schiff E R, Lindsay K, Bodenheimer H C, Jr, Perrillo R P, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. New England Journal of Medicine 1989; 321: 1501–1506
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Svoboda T, Clodi M, Gilly B, Ludwig H, Havelec L, Luger A. Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology 1993; 57: 489–495
   PubMed Web of Science ®Google Scholar
• Bocci V. Central nervous system toxicity of interferons and other cytokines. Journal of Biologically Regulated Homeostasis Agents 1988; 2: 107–118
   PubMed Web of Science ®Google Scholar
• Gauci L. Management of cancer patients receiving interferon alfa-2a. International Journal of Cancer Supplement 1987; 1: 21–30
   PubMedGoogle Scholar
• Dummer R, Hassel J C, Fellenberg F, Eichmuller S, Maier T, Slos P, et al. Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 2004; 104: 1631–1638
   PubMed Web of Science ®Google Scholar
• Heinzerling L M, Urbanek M, Funk J O, Peker S, Bleck O, Neuber K, et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89: 1835–1844
   PubMed Web of Science ®Google Scholar